Market Place
Sourcing Support
CStone Submits Clinical Trial Application for CS2009 in Australia
22 Dec 2024 //
PR NEWSWIRE
CStone: CS5001 Shows Safety, Efficacy in Advanced Lymphoma Patients
08 Dec 2024 //
PR NEWSWIRE
CStone MHRA Approves Sugemalimab for First-Line NSCLC in UK
31 Oct 2024 //
PR NEWSWIRE
CStone Reports 2024 Interim Results and Recent Corporate Updates
23 Aug 2024 //
PR NEWSWIRE
CStone`s Sugemalimab Approved In EU For First-Line NSCLC Treatment
26 Jul 2024 //
PR NEWSWIRE
EMA committee recommends approval for CStone Pharma’s Cejemly in combo
05 Jun 2024 //
PHARMABIZ
EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC
03 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
EMA CHMP Recommends Cejemly Approval As 1L NSCLC Treatment
01 Jun 2024 //
PR NEWSWIRE
CStone gets a win for sugemalimab in oesophageal cancer
03 Jan 2023 //
PHARMAPHORUM
EQRx receives MHRA marketing approval for sugemalimab
21 Dec 2022 //
PHARMATIMES
CStone presents updated results of a registrational study of sugemalimab
07 Aug 2022 //
PRNEWSWIRE
Pfizer PD-L1 partner explores sale: Bloomberg
14 Jul 2022 //
FIERCEPHARMA
CStone and Pfizer announce NMPA approval of sugemalimab in NSCLC
06 Jun 2022 //
ASIAONE
CStone announces first patient enrollment in U.S. in Phase 1 trial of CS5001
30 Mar 2022 //
PRNEWSWIRE
EQRx adds armor to its discount checkpoint inhibitor submission
18 Jan 2022 //
ENDPTS
CStone says GEMSTONE-302 study of sugemalimab met endpoint of overall survival
18 Jan 2022 //
PRNEWSWIRE
CStone completes enrollment in two key phase 3 trials of sugemalimab
18 Jan 2022 //
ASIAONE
CStone announces the clinical data from registrational study of Sugemalimab
14 Jan 2022 //
ASIAONE
FDA Approves IND Application of CStone`s CS5001
02 Jan 2022 //
PRNEWSWIRE
Anticancer drug candidate jointly developed by LegoChem & ABL Bio scores US nod
01 Jan 2022 //
KOREABIOMED
CStone announced new drug approval of precision therapy AYVAKIT in GIST
28 Dec 2021 //
ASIAONE
CStone Pharmaceuticals Receives Approval in China for Sugemalimab
22 Dec 2021 //
BUSINESSWIRE
CStone Announced New Drug Approval Of Cejemly (Sugemalimab)
21 Dec 2021 //
BIOSPACE
CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY IN CHINA
21 Dec 2021 //
PRNEWSWIRE
CStone, Jiangsu Hengrui partner and sign agreement on anti-CTLA-4 MAb CS1002
20 Nov 2021 //
PRNEWSWIRE
EQRx, CStone unfurl full lung cancer data for PD-L1 drug
17 Sep 2021 //
ENDPTS
EQRx Presents PIII Data for Sugemalimab with Chemotherapy in Stage IV NSCLC
13 Sep 2021 //
BUSINESSWIRE
NMPA accepts CStone’s NDA for sugemalimab to treat unresectable stage III NSCLC
04 Sep 2021 //
PHARMABIZ
CStone announces positive registrational study
03 Aug 2021 //
PRNASIA
No price competition in PD-(L)1? That might not last long as EQRx, CStone
29 May 2021 //
ENDPTS
CStone Announces the First-in-Class Registrational Clinical Trial Sugemalimab
27 May 2021 //
PRNEWSWIRE
CStone Announces Acceptance of NDA in Hong Kong for Avapritinib
12 May 2021 //
PRNASIA
CStone Announces Acceptance of New Drug Application in Hong Kong for Avapritinib
11 May 2021 //
PRNASIA
CStone Announces NMPA Acceptance of New Drug Application GAVRETO(R)
26 Apr 2021 //
PRNASIA
CStone Announces China NMPA New Drug Approval of Precision Therapy AYVAKIT®
31 Mar 2021 //
PRNASIA
CStone Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib
28 Jan 2021 //
PRESS RELEASE
CStone announces the results of GEMSTONE-302, Sugemalimab
23 Nov 2020 //
FIRSTWORLDPHARMA
CStone Pharma submits NDA for Ivosidenib in Singapore for IDH1-mutated
10 Nov 2020 //
PHARMABIZ
CStone and LegoChem to jointly develop novel antibody drug conjugate
30 Oct 2020 //
PHARMACEUTICAL-TECHNOLOGY
CStone inks deal worth $353.5M for new antibody drug conjugate
28 Oct 2020 //
BIOSPECTRUMASIA
EQRx hands CStone $150M for 2 late-stage checkpoint inhibitors
27 Oct 2020 //
FIERCE BIOTECH
CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint
26 Oct 2020 //
PRNEWSWIRE
CStone announces completion of $200 million share sale to Pfizer
12 Oct 2020 //
BIOSPECTRUMASIA
CStone-Pfizer, Gilead, Takeda-Ovid and more—FiercePharmaAsia
02 Oct 2020 //
FIERCE PHARMA
Pfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in China
30 Sep 2020 //
PHARMAPHORUM
U.S.`s Pfizer to buy 9.9% of CStone Pharmaceuticals for $200 mln
30 Sep 2020 //
REUTERS
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs
29 Sep 2020 //
BUSINESSWIRE
CStone Announces Updated Results from Sugemalimab (CS1001) study
25 Sep 2020 //
BUSINESSINSIDER
Genetron/CStone initiate study of companion diagnostic test for avapritinib
25 Sep 2020 //
GLOBENEWSWIRE
CStone receives US FDA IND clearance to evaluate Sugemalimab Monotherapy
02 Sep 2020 //
BIOSPECTRUMASIA
CStone Announces That OmniAb-derived CS1001 Ph3 Trial Met the Endpoint
06 Aug 2020 //
BUSINESSWIRE
CStone Pharma announces positive results from ph I/II ARROW trial of pralsetinib
10 Jul 2020 //
PHARMABIZ
Burning Rock and CStone Pharmaceuticals reached a strategic collaboration
29 Jun 2020 //
GLOBENEWSWIRE
CStone announces acceptance of its first New Drug Application in mainland China
22 Apr 2020 //
PR NEWSWIRE
CStone submits NDA for the targeted therapy avapritinib in Taiwan
27 Mar 2020 //
PR NEWSWIRE
CStone announces first patient dosed in the Phase III trial of CS1001
08 Jan 2020 //
PR NEWSWIRE
CStone announces first patient dosed in the Phase III trial of CS1001
07 Jan 2020 //
PR NEWSWIRE
CStone announces first patient dosed in the Phase III trial of CS1001
07 Jan 2020 //
PR NEWSWIRE
CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Trial
06 Jan 2020 //
PR NEWSWIRE
Genetron Health Announces Strategic Collaboration with Cstone
13 Dec 2019 //
BUSINESSWIRE
